HTHirotaka Takizawa

Hirotaka Takizawa

*This is an algorithmically generated author record based on publicly available information.

Hirotaka Takizawa has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serum Autoantibodies Against Glycolytic and Mitochondrial Proteins in Esophageal Carcinoma: Diagnostic and Exploratory Prognostic Significance

    by Masaaki Ito, Satoshi Yajima, Takashi Suzuki, Yoko Oshima, Makoto Sumazaki, Fumiaki Shiratori, Bo-Shi Zhang, Shu-Yang Li, Hirotaka Takizawa, Hao Wang, et al.

    Background: Metabolic reprogramming toward aerobic glycolysis, commonly referred to as the Warburg effect, is a hallmark of cancer. Such metabolic alterations may lead to aberrant expression and release of glycolytic and mitochondrial proteins, which can act as tumor-associated antigens and elicit humoral immune responses. However, whether patients with esophageal carcinoma (EC) develop a broad autoantibody response against these metabolic proteins, and whether such an autoantibody profile has diagnostic or prognostic relevance, has not been systematically investigated. Objective: To determine (1) whether serum autoantibodies against 18 proteins involved in glucose metabolism and mitochondrial pathways are broadly elevated in patients with EC and have diagnostic potential; (2) whether combining selected autoantibodies improves diagnostic discrimination; and (3) whether individual or combined autoantibody profiles show exploratory associations with postoperative overall survival. Methods: Serum autoantibody levels against 18 metabolic proteins (SLC2A1, ASPSCR1, GK2, ALDOA, TPI1, GAPDH, PGK1, PGK2, ENO1, PGAM1, PKM, PDHB, PCK1, LDHA, SDHB, FH, IDH, and ATP5B) were measured in 191 patients with EC and 96 healthy donors using AlphaLISA. For diagnostic combination analysis, a multivariable logistic regression model combining ENO1-Ab, PDHB-Ab, and ALDOA-Ab was evaluated in the complete-case cohort. In 91 surgically treated patients, exploratory overall survival analyses were performed using Kaplan–Meier curves and log-rank tests after dichotomization of antibody levels. Results: All 18 autoantibodies were significantly elevated in patients with EC compared with healthy donors (all P < 0.05), with individual AUC values ranging from 0.593 for SDHB-Ab to 0.735 for ENO1-Ab. The three-autoantibody model combining ENO1-Ab, PDHB-Ab, and ALDOA-Ab achieved an AUC of 0.812 (95% CI, 0.751–0.873), with a sensitivity of 68.1% and a specificity of 83.9%, and showed significantly greater diagnostic discrimination than the individual autoantibodies evaluated in the same cohort. In exploratory postoperative overall survival analyses, PCK1-Ab and SDHB-Ab showed significant differences in overall survival by log-rank testing. Several combined autoantibody profiles were also associated with survival differences, including high ENO1-Ab/low PGAM1-Ab, high SDHB-Ab/low FH-Ab, high ALDOA-Ab/high TPI1-Ab, and high PCK1-Ab/high SDHB-Ab versus low PCK1-Ab/low SDHB-Ab. Conclusions: The consistent elevation of autoantibodies against all 18 evaluated metabolic proteins suggests the presence of a broad humoral immune response to metabolic antigens in patients with EC. A three-autoantibody model combining ENO1-Ab, PDHB-Ab, and ALDOA-Ab improved diagnostic discrimination compared with individual markers. Exploratory analyses also identified individual and combined autoantibody profiles associated with postoperative overall survival, warranting further validation in independent cohorts.

  • Open Access

    Stage-Specific Alteration and Prognostic Relationship of Serum Fumarate Hydratase Autoantibodies in Gastric Cancer

    by Natsuko Sasajima, Makoto Sumazaki, Yoko Oshima, Masaaki Ito, Satoshi Yajima, Hirotaka Takizawa, Hao Wang, Shu-Yang Li, Bo-Shi Zhang, Yoichi Yoshida, et al.

    The relationship between energy production and cancer is attracting attention. This study aimed to investigate the clinicopathological significance of fumarate hydratase (FH), a tricarboxylic acid cycle enzyme, in gastric cancer using autoantibodies as biomarkers. The study analyzed 116 patients who underwent gastric cancer surgery and 96 healthy controls. Preoperative serum FH autoantibody (s-FH-Ab) titers were analyzed using an immunosorbent assay with an amplified luminescent proximity homogeneous assay. Receiver operating characteristic analysis was used to determine the cutoff s-FH-Ab titer. Clinicopathological factors and prognosis were compared between the high and low s-FH-Ab groups. The s-FH-Ab levels were significantly higher in the gastric cancer group than in the control group (p = 0.01). Levels were elevated even in patients with stage I gastric cancer compared with healthy controls (p = 0.02). A low s-FH-Ab level was significantly associated with distant metastasis (p = 0.01), peritoneal dissemination (p < 0.05), and poor overall survival (p < 0.01). Multivariate analysis revealed that low s-FH-Ab levels were an independent risk factor for poor prognosis (p < 0.01). Therefore, s-FH-Ab levels may be a useful biomarker for early diagnosis and the prediction of prognosis in patients with gastric cancer.


  • Open Access

    JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases

    by Bo-Shi Zhang, Xiao-Meng Zhang, Masaaki Ito, Satoshi Yajima, Kimihiko Yoshida, Mikiko Ohno, Eiichiro Nishi, Hao Wang, Shu-Yang Li, Masaaki Kubota, et al.

    Inflammation is closely associated with cerebrovascular diseases, cardiovascular diseases, diabetes, and cancers, and it is accompanied by the development of autoantibodies in the early stage of inflammation-related diseases. Hence, it is meaningful to discover novel antibody biomarkers targeting inflammation-related diseases. In this study, Jumonji C-domain-containing 6 (JMJD6) was identified by the serological identification of antigens through recombinant cDNA expression cloning. In particular, JMJD6 is an antigen recognized in serum IgG from patients with unstable angina pectoris (a cardiovascular disease). Then, the serum antibody levels were examined using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay and a purified recombinant JMJD6 protein as an antigen. We observed elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with inflammation-related diseases such as ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers (including esophageal cancer, EC; gastric cancer; lung cancer; and mammary cancer), compared with the levels in healthy donors. The s-JMJD6-Ab levels were closely associated with some inflammation indicators, such as C-reactive protein and intima–media thickness (an atherosclerosis index). A better postoperative survival status of patients with EC was observed in the JMJD6-Ab-positive group than in the negative group. An immunohistochemical analysis showed that JMJD6 was highly expressed in the inflamed mucosa of esophageal tissues, esophageal carcinoma tissues, and atherosclerotic plaques. Hence, JMJD6 autoantibodies may reflect inflammation, thereby serving as a potential biomarker for diagnosing specific inflammation-related diseases, including stroke, AMI, DM, and cancers, and for prediction of the prognosis in patients with EC.


  • Open Access

    JMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases

    by Bo-Shi Zhang, Xiao-Meng Zhang, Masaaki Ito, Satoshi Yajima, Kimihiko Yoshida, Mikiko Ohno, Eiichiro Nishi, Hao Wang, Shu-Yang Li, Masaaki Kubota, et al.

    Atherosclerosis is associated with vascular diseases, diabetes, and cancers. The Jumonji C-domain-containing 6 (JMJD6) gene plays an important role in diverse biological processes. In addition, autoantibodies are reportedly useful in the early diagnosis and treatment of many diseases. Here, JMJD6 was identified by serological identification of antigens by recombinant cDNA expression cloning as an antigen recognized by serum IgG from patients with unstable angina pectoris. Then, we performed amplified luminescent proximity homogeneous assay-linked immunosorbent assay using purified recombinant antigens and found elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with atherosclerosis-related diseases including ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers including esophageal cancer (EC), gastric cancer, lung cancer, and mammary cancer, compared with those in healthy donors. The s-JMJD6-Ab levels were closely associated with hypertension, habitual smoking, and the intima-media thickness, an atherosclerosis index. The better postoperative survival status was shown in patients with EC from the JMJD6-Ab-positive group than the negative group, especially from JMJD6-Ab-positive/PD-L1-negative group and JMJD6-Ab-positive/p53-Ab-negative group than JMJD6-Ab-negative/PD-L1-positive group and JMJD6-Ab-negative/p53-Ab-positive group, respectively. Hence, JMJD6 autoantibodies may reflect atherosclerosis severity, thereby a potential biomarker for atherosclerosis-related diseases including ischemic stroke, AMI, DM, and cancers and for predicting EC prognosis.